Myocardial Infarction Market Size and Share Report 2024-2032

Global Myocardial Infarction Market Analysis

 

Global Myocardial Infarction Market is foreseen to be around US$ 3.43 Billion by 2032 from US$ 2.02 Billion in 2023. The CAGR for the market from 2024 to 2032 is 6.06%.

A myocardial infarction or coronary heart attack is an unstable state of affairs that takes place due to the fact an individual does not have sufficient blood glide to some of the heart muscle. This lack of blood glide can stand up due to many factors however is generally associated with a blockage in one or more heart arteries. The affected coronary heart muscle will start to die without blood go with the flow. If the affected man or woman does now not get blood go with the flow lower back quick, a myocardial infarction can reason permanent coronary heart damage or demise. A coronary heart attack is a life-threatening emergency. Time is crucial in treating a myocardial infarction. A delay of even a couple of minutes can bring about eternal heart damage or demise.

 

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=myocardial-infarction-market-p.php

 

• In 2021, the World Heart Federation said that more than 50% of billion human beings globally remain inspired by using cardiovascular conditions, which accounted for 20.5 million deaths. This is nearly a third of all deaths globally and an increase inside the estimated 121 million CVD deaths.
• In June 2023, the FDA authorized Lodoco (colchicine) to lessen the danger of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in in-person patients. Developed by Agepha Pharma, Lodoco is the first drug legal to treat infection, an underlying motive for atherosclerotic cardiovascular sickness.
• The 2023 Global Heart Hub Heart Failure Awareness Month Campaign targets to train the general public about heart failure. They are searching for ways to elevate attention to heart failure’s signs and dangerous elements and the significance of early detection and effective control. Their advertising marketing campaign for the past years has made a specialty of bringing a hobby to heart failure through the slogan #HighlightHeartFailure and saving lives.
• In August 2023, the NHS established a lifesaving campaign to encourage humans to call 999 while they’ll be having untimely signs and signs of a heart assault, as entries for heart attack cross-return to pre-pandemic tiers.

 

United States myocardial infarction Market

 

The US myocardial infarction (MI) marketplace is predicted to grow because of the increasing occurrence of heart diseases, high healthcare expenditure, and properly evolved healthcare infrastructure. Adopting hybrid operating rooms and progressive remedy technology has also contributed to this boom. US hospitals and clinics are nicely- equipped with ultra-modern remedy devices for essential MI surgical procedures. The price of cardiology approaches, bypass surgical treatment, heart valve substitute surgical operation, and physical therapies accompanied by means of surgical treatment inside the US ranges from $50,000 to $200,000. Critical hospitals contributing to the growth of the MI remedy market include Cleveland Clinic, Mayo Clinic, and New York-Presbyterian University Hospital of Columbia.

Global Myocardial Infarction Company News

 

The foremost firms within the worldwide myocardial infarction enterprise are Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, AstraZeneca, Merck, Daiichi Sankyo, Eli Lilly and Company, Takeda, Novartis, Genentech, Amgen, Regeneron/Sanofi, Boehringer Ingelheim, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, and Mesoblast.

 

• In April 2024, Johnson & Johnson will showcase scientific and real-world evidence from its cardiovascular portfolio at the American College of Cardiology’s 73rd Annual Scientific Session & Expo. The presentation will encompass 11 abstracts, including five oral displays, presenting the healing benefits of step-forward medicines together with XARELTO® (rivaroxaban) and interventional technology, along with those from Abiomed® and Biosense Webster® to treat cardiovascular diseases.
• In March 2024, the FDA permitted the weight-loss drug Wegovy through Novo Nordisk to lessen the danger of significant cardiovascular headaches in people with obesity and heart disease.
• In August 2023, Royal Philips showcased the way it integrates AI in cardiac ultrasound and cardiac care to enhance medical self-belief and efficiency.
• In November 2022, Johnson & Johnson agreed to purchase Abiomed for USD 16.6 billion. Abiomed will operate as a separate business and support Johnson & Johnson MedTech’s function in cardiovascular innovation. The acquisition will improve the usual care for coronary heart failure patients.
• In November 2022, a study presented at the American Heart Association observed that tongxiluo, a conventional Chinese natural ingredient, can reduce the mortality hazard after a heart assault by 36%. This substance might be a probable adjuvant therapy for treating STEMI, especially in low-income nations.

 

Related Reports

 

Anti-Venom Market Analysis

Cystic Fibrosis Therapeutics Market Analysis

Active Pharmaceutical Ingredients (API) Market Analysis

 

Drug Class – Market breakup in 9 viewpoints:

 

1. Antiplatelet Agents
2. Glycoprotein IIb/IIIa Inhibitors
3. Antithrombotic Agents
4. Beta-adrenergic Blockers
5. Vasodilators
6. Angiotensin-converting Enzyme (ACE) Inhibitors
7. Angiotensin-receptor Blockers
8. Analgesics
9. Thrombolytics

 

 

Distribution Channel – Market breakup in 4 viewpoints:

 

1. Hospitals
2. Hospital Pharmacies
3. Drug Stores
4. Online Drug Stores

 

 

Countries – Market breakup of 25 Countries:

 

1. North America

 

1.1    United States

1.2    Canada

 

2. Europe

 

2.1    France

2.2    Germany

2.3    Italy

2.4    Spain

2.5    United Kingdom

2.6    Belgium

2.7    Netherlands

2.8    Turkey

 

3. Asia Pacific

 

3.1    China

3.2    Japan

3.3    India

3.4    South Korea

3.5    Thailand

3.6    Malaysia

3.7    Indonesia

3.8    Australia

3.9    New Zealand

 

4. Latin America

 

4.1    Brazil

4.2    Mexico

4.3    Argentina

 

5. Middle East & Africa

 

5.1    Saudi Arabia

5.2    UAE

5.3    South Africa

 

 

All the Key players have been covered from 3 Viewpoints:

 

• Overview
• Recent Development
• Revenue Analysis

 

 

Company Analysis:

 

1. Pfizer
2. Sanofi-Aventis/Bristol-Myers Squibb
3. AstraZeneca
4. Merck
5. Daiichi Sankyo
6. Eli Lilly and Company
7. Takeda
8. Novartis
9. Genentech
10. Amgen
11. Regeneron/Sanofi
12. Boehringer Ingelheim
13. Idorsia Pharmaceuticals
14. Faraday Pharmaceuticals
15. CSL Behring
16. Immediate Therapeutics
17. Mitsubishi Chemical Group
18. Kancera
19. Bayer
20. Recardio
21. Mesoblast

 

About the Company:

 

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.